Rx Products (December 2017)

Pharmacy Times, December 2017 Heart Health, Volume 83, Issue 12

Read about the new Rx Products featured in December.

BYDUREON BCISE

MANUFACTURED BY: AstraZeneca

INDICATION: The FDA has approved AstraZeneca’s Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type 2 diabetes whose blood sugar remains uncon- trolled on 1 or more oral medicines, in addition to diet and exercise, to improve glycemic control.

DOSAGE: Extended-release injectable suspension

FOR MORE INFORMATION: astrazeneca.com

LYRICA CR

MANUFACTURED BY: Pfizer, Inc.

INDICATION: The FDA has approved Lyrica CR (pregabalin) extended-release tablets CV as once-daily therapy of neuropathic pain associated with diabetic peripheral neuropathy and the management of postherpetic neuralgia.

DOSAGE: Capsules: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg

FOR MORE INFORMATION: Pfizer.com

FIASP

MANUFACTURED BY: Novo Nordisk

INDICATION: The FDA has approved Fiasp (fast-acting insulin aspart), a fast-acting mealtime insulin, for the treatment of adults with type 1 and 2 diabetes.

DOSAGE: Injection: 100 units/mL

FOR MORE INFORMATION: novonordisk-us.com

YESCARTA

MANUFACTURED BY: Kite Pharma

INDICATION: The FDA has approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients

with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least 2 other kinds of treatment.

DOSAGE: Cell suspension for infusion

FOR MORE INFORMATION: kitepharma.com